Search
Now showing items 1-10 of 311
Low-grade mucosa-associated lymphoid tissue lymphoma: A retrospective analysis of 97 patients by the Hellenic Cooperative Oncology Group (HeCOG)
(2008)
Background: The aim was to examine characteristics and treatment results of patients with mucosa-associated lymphoid tissue (MALT) non-Hodgkin's lymphomas. Patients and methods: Epidemiological and clinical features of 97 ...
Radiopharmaceuticals in neurological and psychiatric disorders
(2008)
The development of functional brain nuclear medicine techniques and their application in the investigation of neuropsychiatric disorders, have contributed significantly in the illumination of the underlying pathophysiological ...
Clinicopathological study of the expression of hsp27, pS2, cathepsin D and metallothionein in primary invasive breast cancer
(2003)
Expression of the hormone-related proteins hsp27, pS2, and also of cathepsin D (CD) and metallothionein (MT) was studied by immunohistochemistry and analyzed against clinical data in breast cancer. Archived material of ...
The effect of the plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk
(2008)
Plasminogen activator inhibitor (PAI-1), is the central component of the fibrinolytic system. A deletion/insertion (4G/5G) polymorphism in the promoter region of the PAI-1 gene has been correlated with levels of plasma ...
Weekly paclitaxel combined with pegylated liposomal doxorubicin (Caelyx ™) given every 4 weeks: Dose-finding and pharmacokinetic study in patients with advanced solid tumors
(2004)
Background: We aimed to define the maximum tolerated dose (MTD) and characterize the toxicity of the combination of pegylated liposomal doxorubicin (PLD; Caelyx™) and weekly paclitaxel (wPTX), and to investigate pharmacokinetics ...
Dose-dense sequential chemotherapy with epirubicin and paclitaxel in advanced breast cancer
(2001)
The purpose of this study was to evaluate the activity and toxicity profile of dose-dense sequential chemotherapy with epirubicin (EPI) and paclitaxel in advanced breast cancer (ABC). From January to September 1997, 41 ...
Clear evidence that long‐term, low‐dose tamoxifen treatment can induce ocular toxicity a prospective study of 63 patients
(1992)
The current study has prospectively investigated the incidence and course of ocular toxicity after low‐dose tamoxifen treatment. Sixty‐three patients with cancer who could be examined were analyzed. Tamoxifen was administered ...
Paclitaxel in combination with carboplatin or gemcitabine for the treatment of advanced head and neck cancer
(1997)
We performed a phase II study to evaluate the activity and toxicity of the combination of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and carboplatin as first-line treatment in patients with recurrent ...